STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for ...
STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for ...
News Medical on MSN5d
Neurofilament light as a translational biomarker from preclinical drug discovery to clinical applicationNeurofilament light (NFL) is a powerful and sensitive biomarker for tracking neuronal health and disease progression.
Feb. 6, 2025 — A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect ... among Americans is 42%, more than double ...
Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...
When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...
A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving early Alzheimer’s diagnosis. Unlike amyloid-beta, tau neurofibrillary ...
Many peptide medications like glucagon-like peptide-1 (GLP-1) receptor agonists were initially developed to treat type 2 diabetes. One unexpected side effect of these drugs is weight loss.
BioMS Medical evaluated synthetic human MBP peptide 82–98 (MBP8298; BioMs Medical) in a placebo-controlled double-blinded Phase II clinical trial in 32 patients with progressive multiple sclerosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback